MedTrace Logo

Alternating and Direct Current Stimulation for Neuropathic Eye Pain

NCT05931250 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-07-06

No results posted yet for this study

Summary

The goal of this clinical intervention is to test if two forms of transcranial current stimulation, transcranial direct current stimulation (tDCS) or transcranial alternating current stimulation (tACS) can alleviate neuropathic eye pain in a sample of 20 patients.

The main aims are:

* Test if tDCS/tACS can alleviate neuropathic eye pain and/or other cerebral symptoms: brain fatigue, migraine, light sensitivity, etc.
* Test if one stimulation method is superior to the other Patients will be treated for a total of fifteen 30-minute stimulation sessions, three times a day over a five-day period, each stimulation separated by approximately 4 hours, with either active tACS or tDCS over the scalp corresponding to primary sensory and motor areas.

The patients will have questionnaires to monitor subjective experiences and pupillometry before and after treatment to monitor experimental outcomes.

Conditions

  • Eye Pain
  • Neuropathy, Optic
  • Cerebral Injury

Interventions

DEVICE

DC-Stimulator Plus (NeuroConn GmbH, Germany)

Transcranial alternating current stimulation

DEVICE

Sooma direct current stimulator (Sooma, Finland)

Transcranial direct current stimulation

Sponsors & Collaborators

  • Linkoeping University

    collaborator OTHER_GOV

  • Neil Lagali

    lead OTHER

Principal Investigators

  • Neil Lagali, PhD · RegionÖstergötland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-16
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05931250 on ClinicalTrials.gov